Viehbacher, "Biogen") announced today that the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI®" has been launched in South Korea. LEQEMBI received the Ministry ...

Lecanemab, marketed as Leqembi, is the first drug targeting the root cause of Alzheimer’s disease to be approved by the ...

Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...

Eisai (ESAIY) and Biogen (BIIB) announced that the humanized anti-soluble aggregated amyloid-beta, or Abeta, monoclonal antibody Leqembi has ...

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

November is National Alzheimer’s Awareness Month.The Alliance for Aging Research is using this month to raise awareness about ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

first session of receive the newly FDA approved Alzheimer's treatment Leqembi while Williford's wife Cynthia Byron-Williford, 59, right, watches at Abington Neurological Associates in Abington ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

Viehbacher, "Biogen") announced today that the humanized anti-soluble aggregated amyloid-beta (Aß) monoclonal antibody "LEQEMBI®" has been launched in South Korea. LEQEMBI received the ...

Our editors also may be in touch with follow-up questions. Leqembi manufacturers Eisai and Biogen priced the drug at $26,500 for a year’s supply. Meanwhile, FDA approval made the drug eligible ...

STOCKHOLM, Nov. 27, 2024 /PRNewswire/ - BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced today that Leqembi ® (generic name: lecanemab) has been launched in South Korea.